Sareum Holdings plc
("Sareum" or the "Company")
Exercise
of Warrants
Cambridge, UK, 7 May 2024 -
Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology
company developing next-generation kinase inhibitors for autoimmune
disease and cancer, announces that it has received an exercise of
warrants notice from RiverFort Global Opportunities PCC Ltd
("RiverFort") to subscribe
for a total of 1,106,986 new ordinary shares in the capital of the
Company (the "New Ordinary
Shares") at a price of 10 pence per New Ordinary Share for a
total consideration to the Company of £110,698.60.
As announced on 3 August 2023, the
warrants were issued in connection with the Equity Prepayment
Facility (the "RiverFort
Facility") provided by
RiverFort to the Company. Following this exercise of warrants,
RiverFort hold zero warrants over shares in the Company.
As noted in Sareum's announcement of
23 April 2024, the Company has settled the full outstanding balance
of, and does not intend to make any further withdrawals pursuant
to, the RiverFort Facility.
Admission and Total Voting Rights
Application has been made to the
London Stock Exchange plc for the admission of the 1,106,986 New
Ordinary Shares to trading on AIM ("Admission"). It is expected that
Admission will occur at 8.00 a.m. (London time) on or around Monday
13 May 2024. The New Ordinary Shares will rank pari passu with the existing ordinary
shares.
Immediately following Admission, the
total number of ordinary shares in issue will be 107,945,783 and
the total number of voting rights will therefore be
107,945,783, and this
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure and
Transparency Rules.
For Further
Information:
Sareum
Holdings plc
Tim Mitchell,
CEO
|
01223 497700
ir@sareum.co.uk
|
Strand Hanson
Limited (Nominated Adviser)
James Dance / James Bellman
|
020 7409
3494
|
Peel Hunt LLP
(Joint Corporate Broker)
|
020 7418
8900
|
James Steel / Patrick Birkholm
|
|
Hybridan LLP (Joint
Corporate Broker)
Claire Noyce
|
020 3764
2341
|
ICR Consilium
(Financial PR)
Jessica Hodgson / Davide Salvi / Kumail Waljee
|
0203 709
5700
|
About
Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage
biotechnology company developing next generation kinase inhibitors
for autoimmune disease and cancer.
The Company is focused on developing next
generation small molecules which modify the activity of the JAK
kinase family and have best-in-class potential. Its lead candidate,
SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a
potential treatment for a range of autoimmune diseases and has
entered Phase 1a/b clinical development with an initial focus on
psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1
inhibitor with a potential application for cancer
immunotherapy.
Sareum Holdings plc is based in Cambridge, UK,
and is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit
the Company's website at www.sareum.com